Healthcare / Drug Manufacturers - Specialty & GenericTaipei Exchange
$6.49
-0.42 (-6.08%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-55.7M · quality 70.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-30.6%
↓Gross Margin
N/A
•Debt/Equity
0.19
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.86x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-67.2M · FCF $-58.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $5.0M | $1.0M | $2.7M |
| Net Income | $-67.2M | $-67.2M | $-50.6M | $-43.8M | $-31.3M |
| EBITDA | $-54.6M | $-54.6M | $-42.3M | $-39.0M | $-28.1M |
| EPS | — | — | -0.12 | -0.11 | -0.08 |
| Gross Margin | — | — | 84.3% | 57.3% | 43.7% |
| Operating Margin | — | — | -1088.9% | -4423.0% | -1152.9% |
| Net Margin | — | — | -1018.9% | -4241.6% | -1166.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.19 | 0.19 | 0.16 | 0.11 | 0.24 |
| Current Ratio | 8.84 | 8.84 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-58.1M | $-58.1M | $-45.8M | $-55.7M | $-94.5M |
| Returns | |||||
| ROE | -30.6% | -30.6% | -17.4% | -11.3% | -17.3% |
| Valuation | |||||
| P/B | 12.22 | 12.22 | 18.36 | 18.86 | 20.98 |
| Growth & Yield | |||||
| Revenue Growth | — | — | 380.4% | -61.5% | — |
| EPS Growth | — | — | -9.1% | -33.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-49.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.12 → n/d
Residual
-49.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.